Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6410
    -0.0015 (-0.24%)
     

  • OIL

    83.88
    +1.15 (+1.39%)
     

  • GOLD

    2,396.30
    -1.70 (-0.07%)
     

  • Bitcoin AUD

    97,891.49
    +2,783.96 (+2.93%)
     

  • CMC Crypto 200

    1,280.50
    -32.13 (-2.45%)
     

  • AUD/EUR

    0.6022
    -0.0009 (-0.15%)
     

  • AUD/NZD

    1.0892
    +0.0017 (+0.15%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,207.69
    -178.18 (-1.09%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Inspire Medical Systems, Inc. to Present at the Credit Suisse 30th Annual Healthcare Conference

Inspire Medical Systems, Inc.
·1-min read

MINNEAPOLIS, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021.

Inspire is scheduled to present at 8:00 a.m. Eastern Time. The presentation will be accessible via a live webcast at: https://kvgo.com/cs-2021-healthcare-conf/inspire-medical-systems-inc-nov

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989